EAN 2017: Monoclonal antibody could be an effective treatment for chronic migraine

Written by Jonathan Wilkinson

An international team of researchers has reported findings indicating that a new monoclonal antibody could be effective at preventing frequent migraine attacks. In addition, they concluded that the antibody could reduce the quantity of medication patients take for migraine headaches. The team, based in Denmark, Germany and the USA, presented their results at the 3rd European Academy of Neurology Congress in Amsterdam (the Netherlands). Currently, the only approved treatments for chronic migraine and mediation overuse are topiramate and botulinum toxin A. However, the monoclonal antibody erenumab, which blocks the calcitonin gene-related peptide receptor, has already shown positive results in treating...

To view this content, please register now for access

It's completely free